Participated · Equity · Aug 2026

Network Bio focuses on linking fragmented biorepositories at major academic medical centers to provide trusted, permissioned access to biological samples (blood, tissue), genomic information, and longitudinal clinical data. The company’s work centers on interoperability, standardization, consent management, governance, and privacy-preserving computation to make these assets usable for research, drug discovery, diagnostics, and AI development. Its stated plans include creating federated biological data networks and consent and identity infrastructure that hospitals will trust. Financially, the company recently raised $50 million to advance this infrastructure; the article does not detail other financial metrics, revenue, users, or prior funding rounds. The effort is framed as building an important healthcare AI infrastructure layer by enabling access to high-quality biological samples connected to clinical outcomes.

Participated · Series A · May 2026

Catena Labs, founded by Sean Neville and cofounder Matt Venables, is developing a platform that lets humans establish guardrails for AI agents to move money, including spending limits, permitted payees, and account caps. The company has opened invite-only access to its platform and said most initial transactions will be executed by agents. Catena is pursuing regulatory backing by applying for a national trust bank charter in New York from the Office of the Comptroller of the Currency. It has a team of about 11 employees and plans to hire more as it scales. Financially, Catena raised an $18 million initial round in 2025 and a $30 million Series A in its most recent raise; the company declined to disclose its valuation.

Led · Seed · May 2026

ParcelBio develops an APEXm (Amplified and Prolonged EXpression mRNA) platform that uses novel RNA domains to enhance protein expression and extend activity for mRNA medicines. Its lead program is an in vivo CAR-T therapy targeting pathogenic B cells aimed at achieving deep B-cell depletion for durable, drug-free remission in autoimmune disease. The company is also advancing programs in oncology and encoded protein therapeutics. ParcelBio emphasizes enabling sustained CAR expression without viral delivery or ex vivo manufacturing to create scalable, off-the-shelf therapies. The company is led by cofounders David Weinberg (CEO) and Chris Carlson (CSO) and is based in San Francisco. ParcelBio announced a $13M Seed round to fund further development of its platform and pipeline.

Participated · Series A · Feb 2026

SiFi develops cloud software that lets finance teams issue corporate cards, automate expense reporting, and execute vendor payments from a single dashboard. The system provides real-time visibility into outlays, enforces spending policies, and streamlines reconciliations. More than 3,500 organizations across Saudi Arabia now use the product, highlighting strong early adoption. To deepen its value proposition, the company plans to layer additional finance workflows and enhance AI-driven features for analytics and policy enforcement. Management’s stated goal is to evolve into a full-suite finance-management platform. Following its latest fund-raise, SiFi’s cumulative capital stands at over $34 million, giving it resources to accelerate product development and regional expansion. Revenue figures were not disclosed in the article.

Participated · Series D · Jan 2026

OpenEvidence operates a specialized medical superintelligence platform that serves as a "brain extender" for clinicians by synthesizing answers exclusively from trusted medical journals and data. Its orchestration of proprietary, sub-specialist AI models – coordinated by a central “conductor” agent – is designed to surface the highest-quality, most accurate medical guidance available. The service is free to doctors and ad-supported, and it is already used daily by more than 40 % of U.S. physicians across over 10,000 hospitals and medical centers. In December 2025 alone, the system powered roughly 18 million clinical consultations, up from about 3 million per month a year prior, and over the past year doctors using OpenEvidence treated more than 100 million Americans. The rapid adoption helped the company surpass $100 million in annual revenue less than a year after building its commercial team. OpenEvidence differentiates itself through exclusive content partnerships with the New England Journal of Medicine, the American Medical Association, the National Comprehensive Cancer Network, and the American College of Cardiology, among others. These relationships, combined with its narrow training corpus and multi-agent architecture, have positioned the company as the most widely used AI tool by U.S. physicians.